XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.40

+0.8%

9:53 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (13946)	7/4/2000 1:18:40 AM
From: aknahow	Read Replies (3) of 17367

Robert, what do you mean nit pick, which indications will work or not work? I said, "if you think about it it will not be approved for an indication that can be cured better by something already the standard of care." This is not nit picking! It is stating the obvious and is really a statement of confidence that Neuprex and BPI peptides may well "cure" better than the existing standard of care. To think that any drug would get approved when the existing standard of care was better, (in the broadest sense cures as quickly and safely and cost less), is not logical.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next